A Democratic bill with 5 Democratic cosponsors · See all 5 cosponsors
Last activity — Referred to the House Committee on Energy and Commerce.
In committee
Introduced and handed to a committee in the chamber it started in.
The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.
Its path through Congress
- Introduced
- In Committee
What this bill would do
The GRAS Act aims to amend the Federal Food, Drug, and Cosmetic Act regarding substances considered generally recognized as safe. It requires people using such substances to notify the FDA and meet specific procedural requirements for new uses. The bill also mandates that the Secretary systematically reassess the safety of certain substances every three years. To support these efforts, it provides for the authorization of resources and the collection of fees. Additionally, it establishes new definitions for terms like carcinogenic and reproductive toxicity.
Yes· 3 of 5
- Scored +6
Does this make what the government does easier for the public to see?
The bill requires the FDA to make safety notices, supporting data, and statements publicly available on its website.
- Scored +5
Does this make the government pay for what it commits to?
The bill authorizes the collection of fees from manufacturers to cover the costs of safety reviews and reassessments.
- Scored +3
Would women be better off under this?
The bill explicitly requires monitoring for reproductive and developmental toxicity.
The opposite
- Scored -4
Does this make it easier to run a small business?
The bill imposes new notification requirements and potential fees on those treating substances as generally recognized as safe.
Who it would affect, and how
Potential Positive Impacts for People
-
Increased Safety Oversight: The bill requires the Secretary to systematically reassess the safety of at least 10 substances or classes of substances every three years (Section 4).
-
Enhanced Transparency: The Secretary must make notices and supporting data publicly available on the FDA website and provide a 60-day period for public comment (Section 3).
-
Rigorous Safety Standards: Notices for new uses must include detailed information regarding cumulative effects, hazard, dose response, exposure, and the prevention of cancer or reproductive and developmental toxicity (Section 3).
-
Prevention of Conflicts of Interest: The Secretary is authorized to object to a notice if an expert providing the data appears to have a conflict of interest (Section 3).
Potential Negative Impacts for People
-
New Burdens on Manufacturers: Any person intending to treat a food substance as generally recognized as safe for a new use must submit a notice to the Secretary including specific, detailed information (Section 3).
-
Potential Financial Costs: The bill allows for the collection of fees from people filing notices or those subject to a reassessment to cover the costs of these activities (Section 6).
-
Risk of Penalties: The Secretary is authorized to assess civil monetary penalties in cases of violations regarding reassessments (Section 4).
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Tap or hover a score for the reason it gave.
- Governance And Ideology
- Does this make what the government does easier for the public to see? — The bill requires the FDA to make safety notices, supporting data, and statements publicly available on its website.
- Demographic And Interest Groups
- Would women be better off under this? — The bill explicitly requires monitoring for reproductive and developmental toxicity. Would households on low incomes be better off under this? — The bill provides stricter safety oversight for food substances consumed by the general population.
- Healthcare
- Does this make health care easier to get in general? — The bill enhances food safety oversight which contributes to long-term public health and safety.
- Economy And Finance
- Does this make the government pay for what it commits to? — The bill authorizes the collection of fees from manufacturers to cover the costs of safety reviews and reassessments. Does this make it easier to run a small business? — The bill imposes new notification requirements and potential fees on those treating substances as generally recognized as safe.
- 7/9/2026
- 1 Cosponsor added.
- 2/24/2026
- 2 Cosponsors added.
- 2/3/2026
- 1 Cosponsor added.
- 12/1/2025
- 1 Cosponsor added.
- 8/12/2025
- Referred to the House Committee on Energy and Commerce.
- Introduced in House
Ro KhannaDemocrat · California
Eleanor NortonDemocrat · District of Columbia
Kim SchrierDemocrat · Washington
Paul TonkoDemocrat · New York
Rashida TlaibDemocrat · Michigan